QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Packer, R. J. Articles by Rorke, L. B. Search for Related Content PubMed PubMed Citation Social Bookmarking                   What's this?

Medulloblastoma: Clinical and biologic aspects

Departments of Neurology [R.J.P.], Pediatrics [R.J.P.], Neurosurgery [P.C.], and Diagnostic Imaging [G.V.], Children's National Medical Center, Washington, DC 20010; Departments of Neurology [R.J.P.], Pediatrics [R.J.P.], Neurosurgery [P.C.], and Radiology [G.V.], The George Washington University Hospital, Washington, DC 20010; and the Department of Pathology, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104 [L.B.R.]

¹ Address correspondence and reprint requests to Roger J. Packer, MD, Department of Neurology, Children's National Medical Center, 111 Michigan Avenue, NW, Washington, DC 20010.

Abstract

Medulloblastoma is the most common childhood primary CNS tumor, and treatment approaches have evolved over the past three decades. The biologic under-pinnings of medulloblastoma are not fully characterized, but recent work has identified new, important directions for research. Stratification of patients with medulloblastoma into risk groups is the backbone of most ongoing therapeutic studies. Patients are usually characterized as being either average risk or poor risk, although an intermediate risk group may exist. Standard treatment for older children with medulloblastoma consists of radiation and, for most, chemotherapy. Children with nondisseminated disease at the time of diagnosis have been reported to have as high as an 80% five-year disease-free survival rate after treatment with reduced dose (2340 cGy) craniospinal irradiation, local boost radiation therapy (5500 cGy), and chemotherapy, given during and after radiation therapy. Preradiation chemotherapy has yet to be shown to be of benefit for children with medulloblastoma. Children with disseminated disease are a highly problematic subgroup of patients to treat. A variety of new approaches are being studied, most of which are intensifying chemotherapy either prior to or after radiation. Long-term survivors of medulloblastoma are at significant risk for permanent endocrinologic, cognitive, and psychological sequelae. Infants and very young children with medulloblastoma remain a difficult therapeutic challenge because they have the most virulent form of the disease and are at highest risk for treatment-related sequelae.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				O. Veiseh, C. Sun, C. Fang, N. Bhattarai, J. Gunn, F. Kievit, K. Du, B. Pullar, D. Lee, R. G. Ellenbogen, et al. Specific Targeting of Brain Tumors with an Optical/Magnetic Resonance Imaging Nanoprobe across the Blood-Brain Barrier Cancer Res., August 1, 2009; 69(15): 6200 - 6207. [Abstract] [Full Text] [PDF]

				T. J. Abouantoun and T. J. MacDonald Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor Mol. Cancer Ther., May 1, 2009; 8(5): 1137 - 1147. [Abstract] [Full Text] [PDF]

				R. J. Packer Childhood Brain Tumors: Accomplishments and Ongoing Challenges J Child Neurol, October 1, 2008; 23(10): 1122 - 1127. [Abstract] [PDF]

				F. Nejat, M. El Khashab, and J. T. Rutka Initial Management of Childhood Brain Tumors: Neurosurgical Considerations J Child Neurol, October 1, 2008; 23(10): 1136 - 1148. [Abstract] [PDF]

				T. J. MacDonald Aggressive Infantile Embryonal Tumors J Child Neurol, October 1, 2008; 23(10): 1195 - 1204. [Abstract] [PDF]

				S. R. Parathath, L. A. Mainwaring, A. Fernandez-L, D. O. Campbell, and A. M. Kenney Insulin receptor substrate 1 is an effector of sonic hedgehog mitogenic signaling in cerebellar neural precursors Development, October 1, 2008; 135(19): 3291 - 3300. [Abstract] [Full Text] [PDF]

				J. C. Buckner, P. D. Brown, B. P. O'Neill, F. B. Meyer, C. J. Wetmore, and J. H. Uhm Central Nervous System Tumors Mayo Clin. Proc., October 1, 2007; 82(10): 1271 - 1286. [Abstract] [Full Text] [PDF]

				R. Vibhakar, G. Foltz, J.-g. Yoon, L. Field, H. Lee, G.-y. Ryu, J. Pierson, B. Davidson, and A. Madan Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma Neuro-oncol, April 1, 2007; 9(2): 135 - 144. [Abstract] [Full Text] [PDF]

				E. E. Bar, A. Chaudhry, M. H. Farah, and C. G. Eberhart Hedgehog Signaling Promotes Medulloblastoma Survival via BclII Am. J. Pathol., January 1, 2007; 170(1): 347 - 355. [Abstract] [Full Text] [PDF]

				S.-K. Kim, S. U. Kim, I. H. Park, J. H. Bang, K. S. Aboody, K.-C. Wang, B.-K. Cho, M. Kim, L. G. Menon, P. M. Black, et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin. Cancer Res., September 15, 2006; 12(18): 5550 - 5556. [Abstract] [Full Text] [PDF]

				R. J. Packer, A. Gajjar, G. Vezina, L. Rorke-Adams, P. C. Burger, P. L. Robertson, L. Bayer, D. LaFond, B. R. Donahue, M. H. Marymont, et al. Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma J. Clin. Oncol., September 1, 2006; 24(25): 4202 - 4208. [Abstract] [Full Text] [PDF]

				B. A. Hatton, P. S. Knoepfler, A. M. Kenney, D. H. Rowitch, I. M. de Alboran, J. M. Olson, and R. N. Eisenman N-myc Is an Essential Downstream Effector of Shh Signaling during both Normal and Neoplastic Cerebellar Growth. Cancer Res., September 1, 2006; 66(17): 8655 - 8661. [Abstract] [Full Text] [PDF]

				A. R. Hallahan, J. I. Pritchard, S. Hansen, M. Benson, J. Stoeck, B. A. Hatton, T. L. Russell, R. G. Ellenbogen, I. D. Bernstein, P. A. Beachy, et al. The SmoA1 Mouse Model Reveals That Notch Signaling Is Critical for the Growth and Survival of Sonic Hedgehog-Induced Medulloblastomas Cancer Res., November 1, 2004; 64(21): 7794 - 7800. [Abstract] [Full Text] [PDF]

				W. Xu, A. Janss, and T. Moshang Adult Height and Adult Sitting Height in Childhood Medulloblastoma Survivors J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4677 - 4681. [Abstract] [Full Text] [PDF]

				R. J. Packer, J. G. Gurney, J. A. Punyko, S. S. Donaldson, P. D. Inskip, M. Stovall, Y. Yasui, A. C. Mertens, C. A. Sklar, H. S. Nicholson, et al. Long-Term Neurologic and Neurosensory Sequelae in Adult Survivors of a Childhood Brain Tumor: Childhood Cancer Survivor Study J. Clin. Oncol., September 1, 2003; 21(17): 3255 - 3261. [Abstract] [Full Text] [PDF]

				S. Gururangan, C. McLaughlin, J. Quinn, J. Rich, D. Reardon, E. C. Halperin, J. Herndon II, H. Fuchs, T. George, J. Provenzale, et al. High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Children and Adults With Newly Diagnosed Pineoblastomas J. Clin. Oncol., June 1, 2003; 21(11): 2187 - 2191. [Abstract] [Full Text] [PDF]

				T. J. MacDonald, B. R. Rood, M. R. Santi, G. Vezina, K. Bingaman, P. H. Cogen, and R. J. Packer Advances in the Diagnosis, Molecular Genetics, and Treatment of Pediatric Embryonal CNS Tumors Oncologist, April 1, 2003; 8(2): 174 - 186. [Abstract] [Full Text] [PDF]

				B. Geoerger, K. Kerr, C.-B. Tang, K.-M. Fung, B. Powell, L. N. Sutton, P. C. Phillips, and A. J. Janss Antitumor Activity of the Rapamycin Analog CCI-779 in Human Primitive Neuroectodermal Tumor/Medulloblastoma Models as Single Agent and in Combination Chemotherapy Cancer Res., February 1, 2001; 61(4): 1527 - 1532. [Abstract] [Full Text]

				R. J. Packer, J. M. Boyett, A. J. Janss, T. Stavrou, L. Kun, J. Wisoff, C. Russo, R. Geyer, P. Phillips, M. Kieran, et al. Growth Hormone Replacement Therapy in Children With Medulloblastoma: Use and Effect on Tumor Control J. Clin. Oncol., January 15, 2001; 19(2): 480 - 487. [Abstract] [Full Text] [PDF]

				J. A. Biegel, B. Fogelgren, J.-Y. Zhou, C. D. James, A. J. Janss, J. C. Allen, D. Zagzag, C. Raffel, and L. B. Rorke Mutations of the INI1 Rhabdoid Tumor Suppressor Gene in Medulloblastomas and Primitive Neuroectodermal Tumors of the Central Nervous System Clin. Cancer Res., July 1, 2000; 6(7): 2759 - 2763. [Abstract] [Full Text]